Decision approving the import and use of the medicinal product Sotrovima for the treatment of COVID-19 The Minister of Health, having regard to the law of 25 March 1964 on medicinal products, Article 6quater, Paragraph 1, paragraph 5°; having regard to the Royal Decree of 14 December 2006 on medicinal products for human and veterinary use, Article 110, paragraph 3; having regard to the opinion of the Finance inspector given on September 2021; having regard to the laws of the Council of State, coordinated on 12 January 1973, Article 3, § 1; Considering the urgent need; Considering the current pandemic situation of COVID-19, a disease caused by the SARS-CoV-2 virus, in Belgium and the rest of the world; Consider the disease-inducing and contagious character of the SARS-CoV-2 virus, its various variants circulating in Europe (see: https://www.ecdcdc.eu/en/COVID-19/variants- concern) and the significant impact on the portability, severity and/or immunity which will probably affect theWhereas the Scientific Opinion of 21/05/2021 of the Committee for Medicinal Products for Human Use (CHMP) of the Committee for Medicinal Products for Human Use (the Committee for Medicinal Products for Human Use (the Committee for Medicinal Products for Human Use (the Committee for Medicinal Products for Human Use) of the European Medicines Agency (the Committee for Medicinal Products for Human Use) of the European Medicines Agency (the Committee for Human Use (the Committee for Medicinal Products for Human Use (the Committee for Medicinal Products for Human Use (the Committee for Human Use)) of 21/05/2021 of the Committee for Medicinal Products for Human Use (the Committee for Medicinal Products for Human Use (the Committee) of the European Medicines Agency (the Committee) of 21/05/2021 of the Committee for Human Use (the Committee for Medicinal Products for Human Use (the Committee for Human Use) of the Committee for Human Use (the Committee for Human Use) of the European Medicines Agency (the Committee) of the European Medicines Agency (the Committee)) of 21/05/2021 of the Committee for Medicinal Products for Human Use (the Committee for Human Use (the Committee) of Human Use (the Committee for Human Use) of Human Use (the Committee)), which decided that, on the basis of the basis of available preliminary data from the clinical study that this clinical study could be used for the treatment of patients with COVID-19 who do not need oxygen therapy and who are at risk to develop a serious form of COVID-19 to develop a serious use of COVID-19; Whereas the recommendations concerning the recommendations concerning the use, distribution of the distribution, distribution, the distribution, the distribution, the distribution, the distribution, the distribution, the distribution, the distribution, the target of the Population, the Population, the Population, the Population, the Population, the Population of the Organisation for Safety of the Organisation for Health and the Organisation for Safety of the Organisation for Safety of the Protection of the Organisation for Safety of the Organisation for Safety, as well for Safety of the Protection of the Protection of Health for Safety of Health and for Safety of Health and for Safety and for Safety, as annexed to be included in the Protection of Health and for Safety and for Safety of Health for Safety and for Safety for Safety for Safety for Safety for Safety for Safety for Safety for Safety for Safety for Safety for Safety for Safety of the Protection of the Protection of the Protection of the Protection of the Protection of the Protection of the Protection of the Protection of the Protection of the Protection ofDecision to authorise the importation, purchase, delivery and administration of Sotrovima for the treatment of COVID-19 caused by the SARS-CoV-2 virus, under the following conditions: 1° the medicinal product Sotrovima may only be prescribed by a doctor attached to a hospital, as referred to in Article 2 of the Coordinated Law of 10 July 2008 on hospitals and other care institutions, after a prior opinion, of a multidisciplinary expert panel consisting of doctors attached to a university hospital, as referred to in Article 4 of the Coordinated Law of 10 July 2008 on hospitals and other care institutions. This panel of experts shall at least consist of an infectiologist and immunologist. In prescribing and formulating the opinion of the expert panel referred to in the national treatment directive "Interim clinical guidance for adults with suspected or confirm COVID-19 in Belgium'.No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency for the medicinal product in question shall be distributed and used in accordance with the conditions of this Decision. This Decision shall apply immediately until 1 June 2022. Brussels, 28 September 2021. The Minister of Health, Fr. VANDENBROUCKE For the consultation of the table, see picture Faced to be attached to our Decision of 28 September 2021. The Minister of Health, Fr. VANDENBROUCKE